Patch-Test Findings in 1,438 Massachusetts Clinic Patients, 2017–2022

November 12, 2026

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.

Reader question: Which allergens were most often positive and clinically relevant in 1,438 Massachusetts clinic patients?

Study snapshot

Study element	Reported detail
Population	1,438 patients referred to the Massachusetts General Hospital Occupational and Contact Dermatitis Clinic for patch testing from 2017 through 2022.
Design	Single-center retrospective analysis of patch-test and clinical records across a six-year referral period.
Comparator	Allergens and years were compared within the referred clinic population; there was no community or untested control group.
Timepoint	Patch-test episodes recorded during 2017–2022; outcomes were not longitudinal clinical follow-up.
Key result	At least one positive reaction occurred in 1,168 patients (81.2%) and at least one relevant reaction in 1,087 (75.6%). Nickel was positive in 21.5%, hydroperoxides of linalool in 20.4% and balsam of Peru in 11.5%; propylene glycol increased while 12 allergens decreased over time at the authors’ corrected significance threshold.
Funding/conflict context	The indexed abstract does not state funding or conflict disclosures. The clinic study did not evaluate Dr. Arsy #003.

What was actually measured?

At least one positive reaction occurred in 1,168 patients (81.2%) and at least one relevant reaction in 1,087 (75.6%). Nickel was positive in 21.5%, hydroperoxides of linalool in 20.4% and balsam of Peru in 11.5%; propylene glycol increased while 12 allergens decreased over time at the authors’ corrected significance threshold.

The analysis is useful for changing allergen patterns in a tertiary referral clinic, not for estimating prevalence in the general population or workforce.

The denominator defines the scope. A patch-test clinic, selected case series, compensation registry, online questionnaire, workplace cohort and general-population survey answer different questions. A percentage from one cannot be silently transferred to the others.

What the result does not prove

Retrospective single-center referral data, changing allergens and suppliers, and lack of an untested comparison group limit generalizability and causal interpretation.

Association, timing and biological plausibility can strengthen an occupational interpretation, but observational evidence cannot automatically establish individual causation. Referral patterns, reporting practices, task mix, protective equipment, nonwork exposures and access to care may all change an estimate.

A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors' conclusions, this interpretation or any product.

Exposure detail matters more than the job label

Workers with the same title can handle different materials for different durations. Useful documentation identifies the exact product or process, the route of contact, glove or PPE material, wetness, friction, heat, dust, splash potential, frequency and how symptoms change away from the task.

A symptom survey can identify a pattern, a clinical examination can refine the differential diagnosis, and patch testing can identify delayed sensitization. None of those steps alone proves that a workplace material caused an individual condition. Clinical relevance still requires a credible exposure and time course.

Questions worth recording

Which task, product, glove, tool, metal, resin, cleanser, food, plant, dust or surface came before symptoms?
Where did the change begin, and did it improve on days away or after a process or PPE change?
How often were hands wet, washed, disinfected, occluded, rubbed, heated or exposed to cold?
Were labels, ingredient information and safety-data sheets reviewed with occupational health?
Did the problem affect dexterity, sleep, pace, attendance, work quality or safety?

Prevention comes before cosmetic care

Substitution, closed systems, local exhaust, splash control, safer cleaning methods, training and correctly selected protective equipment address exposure at its source. Gloves are not automatically protective: material, fit, breakthrough time, sweating, reuse and rubber accelerators all matter.

Do not deliberately place workplace products on skin to test a theory. Persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function warrant professional evaluation.

Primary research and guidance

Where Dr. Arsy #003 fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, neutralizes workplace chemicals, is appropriate for every person, or provides pediatric or 24-hour efficacy.

Continue the evidence series

Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace-safety determination.

← Back to Doctor's Notes